If you are:
Only When Necessary: ONLY AVAILABLE IN COMBINATION PRODUCTS THAT ARE ASSIGNED FDA CATEGORY C.
Only When Necessary: FDA C W/COMBO PROD; POSS RISK OF GASTROSCHISIS/SIA WITH 1ST TRIMESTER EXPOSURE
Precaution: INSUFFICIENT DATA AVAILABLE.
Precaution: MAY DECREASE MILK SUPPLY, AND CAUSE IRRITABILITY
Precaution: NOT RECOMMENDED. MAY CAUSE PARADOXICAL EXCITATION/INHIBIT LACTATION.
An adult over 60:
management or monitoring precaution: Cardiovascular-Elderly are more sensitive to tachycardia and hypertensive effects. May exacerbate symptomatic coronary insufficiency. Genitourinary-May cause urinary retention. Neuro/Psych-May worsen cognitive impairment in some elderly with dementia. Insomnia risk.
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating agents preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Giving Panatuss PED to a child under 12:
Contraindication: Not recommended age < 6 years without clinician consultation.
Contraindication: Risk of CNS effects. Not recommended age < 6 years unless clinician consult.
Contraindication: No safety and efficacy age <2 years. CNS excitation and seizure risk in newborns.
Contraindication: High risk of adverse CNS effects. Not recommended for use age < 6 years.